BCL-2 inhibitors like ibrutinib and venetoclax have been used in the treatment of lymphoproliferative disorders like chronic lymphocytic leukemia (CLL) for long enough that mid-term effects of the agents can be analyzed. In this interview, Francesco Forconi, MD, DM, PhD, FRCPath, from the University of Southampton, Southampton, UK, discusses what we know at this stage at the 23rd Congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Results are promising for using these molecules, either as single agents or in combination with anti-CD20 antibodies or BTK inhibitors.
BCL-2 inhibitors: the current landscape
